Utility of Serum Free Light Chains in the Evaluation of Response in Light Chain MM: Results from the IFM/DFCI 2009 Trial


Utility of Serum Free Light Chains in the Evaluation of Response in Light Chain MM: Results from the IFM/DFCI 2009 Trial
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Ola Landgren, MD, PhD (2/9/15)
Corre J et al. Serum free light chains should be the target of response evaluation in light chain multiple myeloma rather than urines: Results from the IFM/DFCI 2009 trial. Proc ASH 2014;Abstract 180.

Dr Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York.